Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1992 1
1997 1
1999 1
2001 1
2002 2
2009 1
2011 1
2012 2
2013 3
2014 3
2015 3
2016 2
2017 2
2018 2
2019 4
2020 4
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Vermersch P, et al. Among authors: truffinet p. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. N Engl J Med. 2024. PMID: 38354138 Clinical Trial.
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.
Tornatore C, Wiendl H, Lublin AL, Geertsen SS, Chavin J, Truffinet P, Bar-Or A. Tornatore C, et al. Among authors: truffinet p. Front Neurol. 2022 Feb 28;13:828616. doi: 10.3389/fneur.2022.828616. eCollection 2022. Front Neurol. 2022. PMID: 35295832 Free PMC article. Review.
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
Kuhle J, Chitnis T, Banwell B, Tardieu M, Arnold DL, Rawlings AM, Geertsen SS, Lublin AL, Saubadu S, Truffinet P, Kappos L. Kuhle J, et al. Among authors: truffinet p. Mult Scler. 2023 Mar;29(3):385-394. doi: 10.1177/13524585221144742. Epub 2023 Jan 12. Mult Scler. 2023. PMID: 36632983 Free PMC article. Clinical Trial.
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M; TERIKIDS Investigators. Chitnis T, et al. Among authors: truffinet p. Lancet Neurol. 2021 Dec;20(12):1001-1011. doi: 10.1016/S1474-4422(21)00364-1. Lancet Neurol. 2021. PMID: 34800398 Clinical Trial.
Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.
Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group. Miller AE, et al. Among authors: truffinet p. Mult Scler Relat Disord. 2019 Aug;33:131-138. doi: 10.1016/j.msard.2019.05.014. Epub 2019 May 24. Mult Scler Relat Disord. 2019. PMID: 31195337 Free article. Clinical Trial.
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, Miller AE, Thangavelu K, Benamor M, Truffinet P, O'Connor PW; TEMSO and TOWER Study Groups. Freedman MS, et al. Among authors: truffinet p. Mult Scler. 2018 Apr;24(4):535-539. doi: 10.1177/1352458517695468. Epub 2017 Mar 17. Mult Scler. 2018. PMID: 28304217 Free PMC article. Clinical Trial.
Natural autoantibodies in schizophrenia.
Galinowski A, Barbouche R, Truffinet P, Louzir H, Poirier MF, Bouvet O, Loo H, Avrameas S. Galinowski A, et al. Among authors: truffinet p. Acta Psychiatr Scand. 1992 Mar;85(3):240-2. doi: 10.1111/j.1600-0447.1992.tb08602.x. Acta Psychiatr Scand. 1992. PMID: 1561897
Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
Miller AE, Olsson TP, Wolinsky JS, Comi G, Kappos L, Hu X, Xu X, Lublin AL, Truffinet P, Chavin J, Delhay JL, Benamor M, Purvis A, Freedman MS; TOWER investigators. Miller AE, et al. Among authors: truffinet p. Mult Scler Relat Disord. 2020 Nov;46:102438. doi: 10.1016/j.msard.2020.102438. Epub 2020 Aug 1. Mult Scler Relat Disord. 2020. PMID: 32911306 Clinical Trial.
33 results